Groowe Groowe / Newsroom / SNY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SNY News

Sanofi American Depositary Shares (Each representing one-half of one ordinary share)

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

globenewswire.com
SNY

DoH and Sanofi Partner to Advance Vaccine Innovation

prnewswire.com
SNY

DoH and Sanofi Partner to Advance Vaccine Innovation

prnewswire.com
SNY

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

globenewswire.com
QNTM SNY BIIB CLNN

Raymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision Oncology

prnewswire.com
SNY

TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million

prnewswire.com
SNY

TrueLab Biopharmaceutical gibt Lizenzvereinbarung mit Bionyra Pharma über zwei monoklonale und bispezifische Antikörper der nächsten Generation zur Behandlung immunvermittelter Entzündungskrankheiten im Wert von bis zu 985 Millionen US-Dollar bekannt

prnewswire.com
SNY

TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million

prnewswire.com
BFLY SNY

TrueLab Biopharmaceutical annonce la signature d'un accord de licence avec Bionyra Pharma pour deux anticorps monoclonaux et bispécifiques de nouvelle génération destinés au traitement des maladies inflammatoires à médiation immunitaire, d'une valeur

prnewswire.com
SNY

Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases

businesswire.com
SNY